Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BARKNASDAQ:DSKENASDAQ:EVLVNASDAQ:HUMA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBARKBARK$1.21+0.4%$1.46$1.01▼$2.56$210.77M1.96823,144 shs684,815 shsDSKEDaseke$8.29-0.1%$8.28$4.06▼$8.34$391.29M2749,200 shs1.24 million shsEVLVEvolv Technologies$3.53+8.6%$3.26$2.01▼$4.65$556.15M1.681.73 million shs2.35 million shsHUMAHumacyte$1.48+0.7%$2.46$1.15▼$9.97$229.58M1.623.58 million shs1.76 million shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBARKBARK-0.83%-4.02%-15.55%-37.92%+7.17%DSKEDaseke0.00%0.00%0.00%0.00%0.00%EVLVEvolv Technologies+2.10%-2.78%+3.40%-17.54%-22.27%HUMAHumacyte+7.30%-5.16%-55.72%-67.97%-62.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBARKBARK1.2987 of 5 stars3.30.00.00.02.50.80.6DSKEDasekeN/AN/AN/AN/AN/AN/AN/AN/AEVLVEvolv Technologies1.5564 of 5 stars3.00.00.00.02.52.50.0HUMAHumacyte2.2718 of 5 stars3.51.00.00.02.13.30.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBARKBARK 2.50Moderate Buy$2.67121.30% UpsideDSKEDaseke 0.00N/AN/AN/AEVLVEvolv Technologies 2.00Hold$5.0041.64% UpsideHUMAHumacyte 3.00Buy$13.71826.64% UpsideCurrent Analyst Ratings BreakdownLatest HUMA, DSKE, EVLV, and BARK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.003/12/2025HUMAHumacyteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$15.00 ➝ $15.003/7/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.002/27/2025HUMAHumacyteBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy2/26/2025HUMAHumacyteD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$25.00 ➝ $25.00(Data available from 4/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBARKBARK$490.26M0.43N/AN/A$0.79 per share1.53DSKEDaseke$1.57B0.25$1.96 per share4.24$0.83 per share9.99EVLVEvolv Technologies$89.22M6.23N/AN/A$0.97 per share3.64HUMAHumacyte$1.57M146.23N/AN/A$0.13 per share11.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBARKBARK-$37.01M-$0.19N/AN/AN/A-6.47%-15.34%-6.55%6/2/2025 (Estimated)DSKEDaseke-$17.70M-$0.59N/A∞N/A-1.13%-30.76%-1.51%N/AEVLVEvolv Technologies-$106.25M-$0.14N/AN/AN/A-21.42%-28.57%-14.76%5/8/2025 (Estimated)HUMAHumacyte-$110.78M-$1.26N/AN/AN/AN/A-942.81%-93.82%5/9/2025 (Estimated)Latest HUMA, DSKE, EVLV, and BARK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/9/2025Q1 2025HUMAHumacyte-$0.19N/AN/AN/A$0.46 millionN/A5/8/2025Q3 2024EVLVEvolv Technologies-$0.08N/AN/AN/A$26.40 millionN/A3/28/2025Q4 2024HUMAHumacyte-$0.23-$0.16+$0.07-$0.16$0.64 million$7.23 million2/5/2025Q3 2025BARKBARK-$0.02-$0.04-$0.02-$0.07$126.42 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBARKBARKN/AN/AN/AN/AN/ADSKEDasekeN/AN/AN/AN/AN/AEVLVEvolv TechnologiesN/AN/AN/AN/AN/AHUMAHumacyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBARKBARKN/A1.630.99DSKEDaseke14.521.121.12EVLVEvolv TechnologiesN/A1.741.50HUMAHumacyteN/A1.101.10Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBARKBARK28.76%DSKEDaseke71.45%EVLVEvolv Technologies66.65%HUMAHumacyte44.71%Insider OwnershipCompanyInsider OwnershipBARKBARK14.80%DSKEDaseke5.80%EVLVEvolv Technologies11.20%HUMAHumacyte11.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBARKBARK640174.92 million149.03 millionOptionableDSKEDaseke4,18247.20 million44.46 millionOptionableEVLVEvolv Technologies170157.55 million139.90 millionOptionableHUMAHumacyte150155.12 million111.76 millionOptionableHUMA, DSKE, EVLV, and BARK HeadlinesRecent News About These CompaniesHumacyte, Inc. (HUMA) Ascends But Remains Behind Market: Some Facts to NoteApril 24 at 7:00 PM | zacks.com$5K Birth Reward in Talks; Zepbound Lawsuits; Varenicline for Vape CessationApril 24 at 3:35 PM | msn.comContrasting Genetic Technologies (NASDAQ:GENE) and Humacyte (NASDAQ:HUMA)April 19, 2025 | americanbankingnews.comHumacyte Challenges FDA Petition Amidst ControversyApril 18, 2025 | tipranks.comHumacyte, Inc. (HUMA) Increases Despite Market Slip: Here's What You Need to KnowApril 16, 2025 | zacks.comShamik J. Parikh Buys 7,500 Shares of Humacyte, Inc. (NASDAQ:HUMA) StockApril 16, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) CFO Dale A. Sander Purchases 20,000 SharesApril 16, 2025 | marketbeat.comVanguard Group Inc. Purchases 543,995 Shares of Humacyte, Inc. (NASDAQ:HUMA)April 16, 2025 | marketbeat.comShamik J. Parikh Acquires 7,500 Shares of Humacyte, Inc. (NASDAQ:HUMA) StockApril 15, 2025 | insidertrades.comFranklin Resources Inc. Takes Position in Humacyte, Inc. (NASDAQ:HUMA)April 15, 2025 | marketbeat.comCenterBook Partners LP Makes New $6.46 Million Investment in Humacyte, Inc. (NASDAQ:HUMA)April 11, 2025 | marketbeat.comHumacyte, Inc. (NASDAQ:HUMA) Director Purchases $66,000.00 in StockApril 10, 2025 | marketbeat.comInsider Buying: Humacyte, Inc. (NASDAQ:HUMA) Director Acquires 50,000 Shares of StockApril 9, 2025 | insidertrades.comHumacyte, Inc. (HUMA) Stock Moves -0.68%: What You Should KnowApril 3, 2025 | msn.comHumacyte, Inc. (NASDAQ:HUMA) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comHumacyte Stock (HUMA) Hits Record Low Post Q4 Results Despite FDA Nod for Vascular Trauma TreatmentMarch 31, 2025 | markets.businessinsider.comHumacyte, Inc. (NASDAQ:HUMA) Given Consensus Rating of "Buy" by AnalystsMarch 30, 2025 | marketbeat.comThrivent Financial for Lutherans Has $2.10 Million Stock Holdings in Humacyte, Inc. (NASDAQ:HUMA)March 30, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Issues Quarterly Earnings Results, Beats Expectations By $0.08 EPSMarch 29, 2025 | marketbeat.comHumacyte (NASDAQ:HUMA) Announces Quarterly Earnings Results, Beats Expectations By $0.08 EPSMarch 29, 2025 | marketbeat.comDurham biotech defends lead product after concerns surfaceMarch 28, 2025 | bizjournals.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesAre Tariffs Threatening Disney’s Comeback Story?By Jea Yu | April 9, 2025View Are Tariffs Threatening Disney’s Comeback Story?Signs of a more buyer-friendly housing market emerge for the spring homebuying seasonBy The Associated Press | April 6, 2025View Signs of a more buyer-friendly housing market emerge for the spring homebuying season5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat3 Stocks Near 52-Week Lows With Strong Rebound PotentialBy Gabriel Osorio-Mazilli | March 31, 2025View 3 Stocks Near 52-Week Lows With Strong Rebound Potential2 Healthcare Recession-Resistant Stocks Unaffected by TariffsBy Jea Yu | April 15, 2025View 2 Healthcare Recession-Resistant Stocks Unaffected by TariffsHUMA, DSKE, EVLV, and BARK Company DescriptionsBARK NYSE:BARK$1.20 +0.01 (+0.42%) As of 03:52 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.BARK Inc., a dog-centric company, provides products, services, and content for dogs. It operates in two segments, Direct to Consumer and Commerce. The company serves dogs through monthly subscription services. It is also involved in the design of playstyle-specific toys, satisfying treats, personal meal plans with supplements, and dog-first experiences designed to foster health and happiness of dogs everywhere. In addition, the company offers monthly themed box of toys and treats under the BarkBox and Super Chewer names; personalized meal plans under the BARK Food name; health and wellness products under the BARK Bright name; and dog beds, bowls, collars, harnesses, and leashes under the BARK Home brand. Further, the company sells BARK Home products through BarkShop.com. Additionally, it offers custom collections through online marketplaces, and brick and mortar retailers. The company was formerly known as The Original BARK Company and changed its name to BARK, Inc. in November 2021. BARK Inc. was incorporated in 2011 and is headquartered in New York, New York.Daseke NASDAQ:DSKEDaseke, Inc. provides transportation and logistics solutions in the United States, Canada, and Mexico. It operates in two segments, Flatbed Solutions and Specialized Solutions. The company transports aircraft parts, manufacturing equipment, structural steel, pressure vessels, wind turbine blades, commercial glass, high security cargo, industrial and hazardous waste, arms, ammunition and explosives, lumber, and building and construction materials, as well as heavy machinery, such as construction, mining, and agriculture. It also offers logistical planning and warehousing services. As of December 31, 2023, the company operated 2,971 company-owned tractors and 1,798 independent owned and operated contractors tractors; and 9,669 trailers. Daseke, Inc. is headquartered in Addison, Texas.Evolv Technologies NASDAQ:EVLV$3.53 +0.28 (+8.62%) As of 04:00 PM EasternEvolv Technologies Holdings, Inc. provides artificial intelligence (AI)-based weapons detection for security screening in the United States and internationally. Its products include Evolv Express, a touchless security screening system designed to detect firearms, improvised explosive devices, and tactical knives; and Evolv Insights that provides self-serve access, insights regarding visitor flow and arrival curves, location specific performance, system detection performance, and alarm statistics. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.Humacyte NASDAQ:HUMA$1.48 +0.01 (+0.68%) As of 04:00 PM EasternHumacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection. It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes. The company was founded in 2004 and is headquartered in Durham, North Carolina. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Now Is the Time to Buy ServiceNow—The Rebound Is Real Seismic Shift at Intel: Massive Layoffs Precede Crucial Earnings Rocket Lab Lands New Contract, Builds Momentum Ahead of Earnings Netflix’s Trillion-Dollar Baby Ambition: Realistic or Ridiculous? Chip Giant ASML Gets New Price Targets With Big Upside Salesforce Is Ready to Rebound With Analysts Forecasting Upside What's Behind Bill Ackman Buying Hertz Stock? S&P 500 and Nasdaq-100 Flashed Death Crosses—Should You Worry? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
